Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 1.10
IMMU's Cash to Debt is ranked lower than
78% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 60.34 vs. IMMU: 1.10 )
Ranked among companies with meaningful Cash to Debt only.
IMMU' s 10-Year Cash to Debt Range
Min: 0.33  Med: 10000.00 Max: No Debt
Current: 1.1
Equity to Asset 0.05
IMMU's Equity to Asset is ranked lower than
92% of the 594 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. IMMU: 0.05 )
Ranked among companies with meaningful Equity to Asset only.
IMMU' s 10-Year Equity to Asset Range
Min: -0.58  Med: 0.74 Max: 0.92
Current: 0.05
-0.58
0.92
Interest Coverage No Debt
IMMU's Interest Coverage is ranked higher than
91% of the 375 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. IMMU: No Debt )
Ranked among companies with meaningful Interest Coverage only.
IMMU' s 10-Year Interest Coverage Range
Min: 354.57  Med: 10000.00 Max: 9999.99
Current: No Debt
354.57
9999.99
F-Score: 2
Z-Score: -2.03
M-Score: -4.93
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -1055.66
IMMU's Operating margin (%) is ranked lower than
79% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -69.59 vs. IMMU: -1055.66 )
Ranked among companies with meaningful Operating margin (%) only.
IMMU' s 10-Year Operating margin (%) Range
Min: -782.35  Med: -226.75 Max: 55.69
Current: -1055.66
-782.35
55.69
Net-margin (%) -1067.45
IMMU's Net-margin (%) is ranked lower than
80% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -66.45 vs. IMMU: -1067.45 )
Ranked among companies with meaningful Net-margin (%) only.
IMMU' s 10-Year Net-margin (%) Range
Min: -782.35  Med: -201.72 Max: 60.72
Current: -1067.45
-782.35
60.72
ROE (%) -217.55
IMMU's ROE (%) is ranked lower than
92% of the 761 Companies
in the Global Biotechnology industry.

( Industry Median: -29.50 vs. IMMU: -217.55 )
Ranked among companies with meaningful ROE (%) only.
IMMU' s 10-Year ROE (%) Range
Min: -1147.9  Med: -43.98 Max: 740.72
Current: -217.55
-1147.9
740.72
ROA (%) -95.07
IMMU's ROA (%) is ranked lower than
85% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: -25.57 vs. IMMU: -95.07 )
Ranked among companies with meaningful ROA (%) only.
IMMU' s 10-Year ROA (%) Range
Min: -74.76  Med: -33.58 Max: 74.44
Current: -95.07
-74.76
74.44
ROC (Joel Greenblatt) (%) -2326.32
IMMU's ROC (Joel Greenblatt) (%) is ranked lower than
71% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: -333.14 vs. IMMU: -2326.32 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
IMMU' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1787.04  Med: -181.29 Max: 760.43
Current: -2326.32
-1787.04
760.43
Revenue Growth (3Y)(%) -18.10
IMMU's Revenue Growth (3Y)(%) is ranked lower than
67% of the 404 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. IMMU: -18.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
IMMU' s 10-Year Revenue Growth (3Y)(%) Range
Min: -57.8  Med: 9.85 Max: 83.3
Current: -18.1
-57.8
83.3
EBITDA Growth (3Y)(%) 21.30
IMMU's EBITDA Growth (3Y)(%) is ranked higher than
77% of the 427 Companies
in the Global Biotechnology industry.

( Industry Median: -3.90 vs. IMMU: 21.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
IMMU' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -25.5  Med: -7.80 Max: 54.2
Current: 21.3
-25.5
54.2
EPS Growth (3Y)(%) 28.10
IMMU's EPS Growth (3Y)(%) is ranked higher than
83% of the 413 Companies
in the Global Biotechnology industry.

( Industry Median: -7.70 vs. IMMU: 28.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
IMMU' s 10-Year EPS Growth (3Y)(%) Range
Min: -36.3  Med: -12.60 Max: 84.2
Current: 28.1
-36.3
84.2
» IMMU's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

IMMU Guru Trades in

Q3 2013

IMMU Guru Trades in Q3 2013

Steven Cohen 1,810,000 sh (New)
Jim Simons 260,207 sh (New)
» More
Q4 2013

IMMU Guru Trades in Q4 2013

Paul Tudor Jones 18,678 sh (New)
Jim Simons Sold Out
Steven Cohen 1,398,548 sh (-22.73%)
» More
Q1 2014

IMMU Guru Trades in Q1 2014

Steven Cohen Sold Out
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with IMMU

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 43.32
IMMU's P/B is ranked lower than
99% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. IMMU: 43.32 )
Ranked among companies with meaningful P/B only.
IMMU' s 10-Year P/B Range
Min: 4.32  Med: 10.87 Max: 249
Current: 43.32
4.32
249
P/S 65.00
IMMU's P/S is ranked lower than
86% of the 591 Companies
in the Global Biotechnology industry.

( Industry Median: 11.60 vs. IMMU: 65.00 )
Ranked among companies with meaningful P/S only.
IMMU' s 10-Year P/S Range
Min: 2.97  Med: 28.58 Max: 133.75
Current: 65
2.97
133.75
Current Ratio 12.10
IMMU's Current Ratio is ranked higher than
80% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.37 vs. IMMU: 12.10 )
Ranked among companies with meaningful Current Ratio only.
IMMU' s 10-Year Current Ratio Range
Min: 0.6  Med: 4.28 Max: 12.5
Current: 12.1
0.6
12.5
Quick Ratio 12.04
IMMU's Quick Ratio is ranked higher than
81% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. IMMU: 12.04 )
Ranked among companies with meaningful Quick Ratio only.
IMMU' s 10-Year Quick Ratio Range
Min: 0.59  Med: 4.11 Max: 12.23
Current: 12.04
0.59
12.23
Days Inventory 7.81
IMMU's Days Inventory is ranked higher than
91% of the 399 Companies
in the Global Biotechnology industry.

( Industry Median: 118.21 vs. IMMU: 7.81 )
Ranked among companies with meaningful Days Inventory only.
IMMU' s 10-Year Days Inventory Range
Min: 5.22  Med: 339.57 Max: 559.69
Current: 7.81
5.22
559.69
Days Sales Outstanding 49.10
IMMU's Days Sales Outstanding is ranked higher than
63% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. IMMU: 49.10 )
Ranked among companies with meaningful Days Sales Outstanding only.
IMMU' s 10-Year Days Sales Outstanding Range
Min: 2.57  Med: 34.46 Max: 105.77
Current: 49.1
2.57
105.77

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 123.67
IMMU's Price/Net Current Asset Value is ranked lower than
98% of the 538 Companies
in the Global Biotechnology industry.

( Industry Median: 7.59 vs. IMMU: 123.67 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
IMMU' s 10-Year Price/Net Current Asset Value Range
Min: 4.82  Med: 13.78 Max: 152
Current: 123.67
4.82
152
Price/Tangible Book 61.83
IMMU's Price/Tangible Book is ranked lower than
98% of the 687 Companies
in the Global Biotechnology industry.

( Industry Median: 5.90 vs. IMMU: 61.83 )
Ranked among companies with meaningful Price/Tangible Book only.
IMMU' s 10-Year Price/Tangible Book Range
Min: 3.55  Med: 10.95 Max: 96
Current: 61.83
3.55
96
Price/Median PS Value 3.25
IMMU's Price/Median PS Value is ranked lower than
86% of the 540 Companies
in the Global Biotechnology industry.

( Industry Median: 1.19 vs. IMMU: 3.25 )
Ranked among companies with meaningful Price/Median PS Value only.
IMMU' s 10-Year Price/Median PS Value Range
Min: 0.11  Med: 1.15 Max: 7.14
Current: 3.25
0.11
7.14
Earnings Yield (Greenblatt) (%) -20.09
IMMU's Earnings Yield (Greenblatt) (%) is ranked lower than
72% of the 813 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. IMMU: -20.09 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
IMMU' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -20.09  Med: 5.00 Max: 17.4
Current: -20.09
-20.09
17.4

Analyst Estimate

Jun15 Jun16
Revenue(Mil) 4 5
EPS($) -0.53 -0.56
EPS without NRI($) -0.53 -0.56

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:IM3.Germany,
Immunomedics Inc was incorporated in Delaware in 1982. It is a biopharmaceutical company which develops monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. It has developed advanced proprietary technologies that allow it to create humanized antibodies that can be used either alone in unlabeled or 'naked' form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins, in each case to create targeted agents. Using these technologies, it has built a pipeline of therapeutic product candidates that utilize several different mechanisms of action. Its product candidate, epratuzumab, is currently in two Phase III clinical trials in lupus. In oncology, the Company is planning to launch a Phase III pivotal trial for clivatuzumab labeled with a radioisotope in pancreatic cancer patients. Other solid tumor therapeutics in Phase II clinical development includes 2 antibody-drug conjugates; labetuzumab-SN-38 (IMMU-130) and hRS7-SN-38 (IMMU-132).It also have a majority ownership in IBC Pharmaceuticals, Inc., which is developing a DOCK-AND-LOCK (DNL) method with for making fusion proteins and multifunctional antibodies. DNL is being used particularly to make bispecific antibodies targeting cancers and infectious diseases as a T-cell redirecting immunotherapy, as well as bispecific antibodies for next-generation cancer and autoimmune disease therapies. It has licensed its product candidate, epratuzumab, to UCB S.A., or UCB, for the treatment of all non-cancer indications worldwide. Epratuzumab's advanced clinical testing is for the treatment of systemic lupus erythematosus, or SLE (lupus), in non-Hodgkin lymphoma, or NHL and acute lymphoblastic leukemia, or ALL. During the 2013 fiscal year, it have completed a Phase Ib clinical trial evaluating clivatuzumab tetraxetan (hPAM4) labeled with yttrium-90, or Y-90, with and without low-dose gemcitabine, in pancreatic cancer patients who had received at least 2 prior therapies. It also initiated a randomized Phase Ib study examining the Y-90-labeled clivatuzumab tetraxetan, with and without low-dose gemcitabine, in pancreatic cancer patients who have received at least 2 prior therapies. It is also conducting a National Cancer Institute, or NCI, grant-supported study combining unlabeled veltuzumab with Y-90-labeled epratuzumab tetraxetan in patients with diffuse large B-cell lymphoma, or DLBCL, the aggressive form of NHL. The second ADC in its product pipeline is, labetuzumab-SN-38, which is in a Phase I/II trial in patients with advanced colorectal cancer. In the first half of fiscal 2013, it plan to begin a new study examining the safety and tolerability of its third ADC, hRS7-SN-38, in patients with solid cancers, for which an Investigational New Drug (IND) application has been filed with the Food and Drug Administration (FDA). The Company competes with Biogen Idec, Roche, GlaxoSmithKline, Seattle Genetics, Merck Serono,
» More Articles for IMMU

Headlines

Articles On GuruFocus.com
Immunomedics Inc. Reports Operating Results (10-Q) Feb 04 2011 
Immunomedics Inc. Reports Operating Results (10-Q) Nov 04 2010 
Immunomedics Inc. Reports Operating Results (10-K) Aug 26 2010 
Fastest Growing Magic Formula Stocks: Jiangbo Pharmaceuticals, DragonWave, Immunomedics, Genoptix, P Jul 15 2010 
Immunomedics Inc. Reports Operating Results (10-Q) May 10 2010 
Immunomedics Inc. Reports Operating Results (10-Q) Feb 02 2010 
Immunomedics Inc. Reports Operating Results (10-Q) Nov 06 2009 
Immunomedics Inc. Reports Operating Results (10-K) Aug 27 2009 
Immunomedics Inc. Reports Operating Results (10-Q) May 11 2009 
Immunomedics Inc. Reports Operating Results (10-Q) Feb 09 2009 

More From Other Websites
IMMUNOMEDICS INC Files SEC form 8-K, Other Events Jul 28 2015
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation of Immunomedics Inc. and Its... Jul 28 2015
Was the Immunomedics Sell-Off Too Extreme? Jul 28 2015
IMMUNOMEDICS INC Files SEC form 8-K, Regulation FD Disclosure, Other Events Jul 16 2015
Bulls come back to Immunomedics Jun 18 2015
Is Immunomedics ready to soar? Jun 15 2015
Cancer Drug Conference Gives Sector A Boost Jun 12 2015
How 6 ASCO Biotech Winners Are Focusing on the Future of Cancer Jun 07 2015
IMMUNOMEDICS ANNOUNCES DURABLE RESPONSES IN METASTATIC LUNG CANCER PATIENTS TREATED WITH SACITUZUMAB... Jun 02 2015
IMMUNOMEDICS REPORTS LABETUZUMAB GOVITECAN IS ACTIVE IN RELAPSED METASTATIC COLORECTAL CANCER Jun 02 2015
Immunomedics Reports Labetuzumab Govitecan is Active in Relapsed Metastatic Colorectal Cancer Jun 02 2015
Immunomedics Announces Durable Responses in Metastatic Lung Cancer Patients Treated With Sacituzumab... Jun 02 2015
6 Key Cancer Winners From ASCO Presentations Jun 01 2015
IMMUNOMEDICS REPORTS PROMISING RESULTS WITH SACITUZUMAB GOVITECAN IN PATIENTS WITH METASTATIC... Jun 01 2015
IMMUNOMEDICS REPORTS COMPLETE RESPONSES IN PATIENTS WITH METASTATIC TRIPLE-NEGATIVE BREAST CANCER... Jun 01 2015
Immunomedics Reports Promising Results With Sacituzumab Govitecan in Patients With Metastatic... Jun 01 2015
Immunomedics Reports Complete Responses in Patients With Metastatic Triple-Negative Breast Cancer... Jun 01 2015
IMMUNOMEDICS TO PRESENT AT JEFFERIES 2015 GLOBAL HEALTHCARE CONFERENCE May 26 2015
Immunomedics to Present at Jefferies 2015 Global Healthcare Conference May 26 2015
Immunomedics' Drug Gets Fast Track Status for Lung Cancer - Analyst Blog May 18 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK